Mavrilimumab
Product Specifications
UNSPSC Description
Mavrilimumab (CAM 3001) is a monoclonal antibody that binds to the α subunit of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor and blocks intracellular signalling downstream of GM-CSF. GM-CSF might be a mediator of the hyperactive inflammatory response associated with respiratory failure and death[1].
Target Antigen
c-Fms
Type
Inhibitory Antibodies
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/mavrilimumab.html
Purity
98.37
Solubility
H2O
Smiles
[Mavrilimumab]
References & Citations
[1]Paul C Cremer, et al. Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Rheumatol. 2021 Jun;3(6):e410-e41
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99031/Mavrilimumab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99031/Mavrilimumab-SDS-MedChemExpress.pdf
Clinical Information
Phase 3
CAS Number
1085337-57-0
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1118455-01 0.02 mg (E-Coli)
Recombinant Bifidobacterium longum subsp. infantis Dihydrodipicolinate reductase (dapB)
Ask
View Details MBS1118455-02 0.1 mg (E-Coli)
Recombinant Bifidobacterium longum subsp. infantis Dihydrodipicolinate reductase (dapB)
Ask
View Details 
MBS1118455-03 0.02 mg (Yeast)
Recombinant Bifidobacterium longum subsp. infantis Dihydrodipicolinate reductase (dapB)
Ask
View Details